Re-Imagining Targeted therapy with single-domain antibodies
Single-domain antibodies (“sdAbs”) offer advantageous properties to discover “next generation” therapies.
Sauvie aims to discover, develop and deliver highly targeted therapies that harness sdAbs’ advantageous properties. The initial program aims to harness the potent anti-cancer immune response via CD16a.
PIPELINE
| Programs | Mid Discovery | Late Discovery/Pre-Clinical | Pre-Clinical/Optimization | IND Submission |
|---|---|---|---|---|
|
SV-0400 (CD16a:HER2+) |
 |
 |
 |
 |
|
Program 2 (CD16a:Target 2) |
|
 |
|
|
|
Program 3 (CD16a:Target 3) |
|
|
|
|
|
Program 4 |
|
|
|
|
|
Program 5 |
|
|
|
|
